In silico design of glyco-D,L-peptide antiviral molecules.
Abstract
Backgroundmost licensed antiviral drugs are nucleoside analogs. A recent research focuses on blocking a virus from entering the cells in the viral cell adsorption/entry stage. In this entry mechanism the glycans present on the viral surface play a fundamental role. Homochiral L-peptides acting this fusion mechanism have shown some inhibition of viral infection. Peptides with regularly alternating enantiomeric sequence (L,D-peptides) can assume structures, which are not accessible to the corresponding homochiral molecules. Further, L,D-peptides are less sensitive to the enzymatic digestion.\n\nAimin silico design a L,D-peptide with a high affinity for the viral surface glycans, and consequently able to interfere with its fusion mechanism.\n\nMethodsa 3,6-Mannopentaose (3-6MP) molecule was used to simulate a viral surface glycan. Molecular Dynamics (MD) simulations of 3-6MP and D,L-peptide in water are performed using the force field AMBER12-GLYCAM06i. The binding constant was evaluated from trajectories. The D,L-peptide molecule was modified over the sequence, the length, the terminals and finally glycosylated to attain a very high binding constant value for 3-6MP.\n\nIn addition, the specific interaction between T lymphocyte CD4 glycoprotein and HIV envelope gp120 glycoprotein was studied through MD simulations between a D,L-peptide, bounded to a typical CD4 glycan, and a highly conserved HIV gp120 glycan.\n\nResultsin the case of interaction with 3-6MP molecule, the very effective molecule obtained was H-D-Trp-L-Pro-D-Asn-L-Pro-D-Trp-L-Pro-D-Asn-L-Pro-OH where the Asn residues in position 3 and 7 are glycosylated with alpha-D-Mannopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->6)]-alpha-D-mannopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-1-OH.\n\nIn the case of interaction with HIV envelope, the very effective molecule obtained, able to antagonize the CD4 glycoprotein, was H-D-Trp-L-Pro-D-Asn-L-Pro-D-Trp-L-Pro-D-Asn-L-Pro-OH where the Asn residue in position 3 is glycosylated with alpha-D-galactopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-(1->2)-alpha-D-Mannopyranosyl-(1->3)-[alpha-D-galactopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-(1->2)-alpha-D-Mannopyranosyl-(1->6)]-beta-D-mannopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-(1->4)-N-acetyl-beta-D-glucopyranosyl-1-OH\n\nConclusionthese glycosylated D,L-peptide molecules are very promising representatives of a new class of antiviral agents.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.10
- Field percentile
- 21th percentile
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ReaxFF-guided Optimisation of VIRIP-based HIV-1 Entry Inhibitors
Fabian Zech, Christoph Jung, … Frank Kirchhoff·bioRxiv·Feb 11, 2025
- In vitro selection of cyclized, glycosylated peptide antigens that tightly bind HIV high mannose patch antibodies
Jennifer K. Bailey, Satoru Horiya, … Isaac J. Krauss·ACS Central SciencePeer-reviewed·Jun 12, 2025
- Sulfoglycodendron Antivirals with Scalable Architectures and Activities
Francesco Coppola, Roya Jafari, … Petr Král·Journal of Chemical Information and ModelingPeer-reviewed·Sep 4, 2024
- Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure
A. Shvetsov, Y. Zabrodskaya, … V. Egorov·bioRxiv·Jun 16, 2017
- Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation
V. Pandey, R. K. Tiwari, … K. D. Dubey·bioRxiv·Apr 1, 2019
- Tailored Design of Protein Nanoparticle Scaffolds for Multivalent Presentation of Viral Glycoprotein Antigens
George Ueda, Aleksandar Antanasijevic, … David A. Baker·eLifePeer-reviewed·Aug 3, 2020